Skip to main content
SpringerLink
Log in

Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases

  • Chapter
  • First Online:
Book cover Antibody Therapy

  • 1172 Accesses

Abstract

Autoimmune diseases (AIDs) are a heterogeneous group of conditions with diverse clinical manifestations and complex pathogenesis. Steroids and immunosuppressants are always the cornerstone of treatment of the severe form of most AIDs, but biologic therapies have become a new weapon in the treatment. Biologic therapies have deeply changed the natural history of diseases such as rheumatoid arthritis (RA) and other inflammatory arthritis diseases and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. However, although life-changing in some AIDs, the adverse effects accompanying biologic therapy, such as infection and immunogenicity, and the often disappointing long-term effects with high risk of relapse remain important issues. We still need to identify new candidate targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

AAV:

ANCA-associated vasculitis

AchR:

Acetylcholine receptor

AIDs:

Autoimmune diseases

AIN:

Autoimmune neutropenia

ANCA:

Antineutrophil cytoplasmic antibody

APL:

Antiphospholipid

APS:

Antiphospholipid syndrome

BAFF:

B-cell activating factor

CAD:

Cold-agglutinin disease

CAPS:

Catastrophic antiphospholipid syndrome

CLL:

Chronic lymphocyte leukemia

CVID:

Common variable immunodeficiency syndrome

EGPA:

Eosinophilic granulomatosis with polyangiitis

GCA:

Giant cell arteritis

GPA:

Granulomatosis with polyangiitis

IFNγ:

Interferon-γ

ITP:

Immune thrombocytopenia

IVIg:

Intravenous immunoglobulin

MG:

Myasthenia gravis

MS:

Multiple sclerosis

MuSK:

Muscle-specific tyrosine kinase

PR3:

Proteinase 3

PRCA:

Pure-red cell aplasia

pSS:

Primary Sjögren’s syndrome

RA:

Rheumatoid arthritis

RBC:

Red blood cell

SLE:

Systemic lupus erythematosus

SSc:

Systemic sclerosis

TNF-α:

Tumor necrosis factor-α

TPO-Ras:

Thrombopoietin receptor agonists

wAIHA:

Warm autoimmune hemolytic anemia

References

  • Autrel-Moignet A, Lamy T. Autoimmune neutropenia. Presse Med. 2014;43:e105–18.

    Article  PubMed  Google Scholar 

  • Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119:3691–7.

    Article  CAS  PubMed  Google Scholar 

  • Berentsen S. Therapy for chronic cold agglutinin disease: perspective for further improvements. Blood Transfus. 2013;11:167–8.

    PubMed  PubMed Central  Google Scholar 

  • Berentsen S, Randen U, Oksman M et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130:537–41.

    Google Scholar 

  • Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–90.

    Article  CAS  PubMed  Google Scholar 

  • Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393–9.

    Article  CAS  PubMed  Google Scholar 

  • Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10:51–66.

    Article  CAS  PubMed  Google Scholar 

  • Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med. 2013;42:1317–30.

    Article  PubMed  Google Scholar 

  • Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–85.

    Article  CAS  PubMed  Google Scholar 

  • Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2:99–111.

    Article  PubMed  PubMed Central  Google Scholar 

  • Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120:47–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280–6.

    Article  CAS  PubMed  Google Scholar 

  • Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233–42.

    Article  PubMed  Google Scholar 

  • Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489–503.

    Article  CAS  PubMed  Google Scholar 

  • Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P. Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur J Intern Med. 2015;26:659–65.

    Article  CAS  PubMed  Google Scholar 

  • Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–61.

    Article  CAS  PubMed  Google Scholar 

  • Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14:1072–8.

    Article  CAS  PubMed  Google Scholar 

  • Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155:498–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Godeau B, Stasi R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia? Presse Med. 2014;43:e79–85.

    Article  PubMed  Google Scholar 

  • Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34.

    Article  CAS  PubMed  Google Scholar 

  • Hervier B, Benveniste O. Rituximab in inflammatory myopathies: “a neolithic revolution”. Rev Med Interne. 2015;36:505–8.

    Article  CAS  PubMed  Google Scholar 

  • Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–94.

    Article  CAS  PubMed  Google Scholar 

  • Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124:3228–36.

    Article  CAS  PubMed  Google Scholar 

  • Loricera J, Blanco R, Hernández JL, Pina T, González-Vela MC, González-Gay MA. Biologic therapy in ANCA-negative vasculitis. Int Immunopharmacol. 2015;27:213–9.

    Article  CAS  PubMed  Google Scholar 

  • Lutalo PMK, D’Cruz DP. Biological drugs in ANCA-associated vasculitis. Int Immunopharmacol. 2015;27:209–12.

    Article  CAS  PubMed  Google Scholar 

  • Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92:23–7.

    Article  CAS  PubMed  Google Scholar 

  • Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20.

    Article  CAS  PubMed  Google Scholar 

  • Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129:289–98.

    Article  CAS  PubMed  Google Scholar 

  • Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ponsa I, Espinosab G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review. Med Clin (Barc). 2015;144:97–104.

    Article  Google Scholar 

  • Robeson KR, Kumar A, Keung B, et al. Durability of the rituximab response in acetylcholine receptor autoantibody–positive myasthenia gravis. JAMA Neurol. 2017;74:60–6.

    Article  PubMed  Google Scholar 

  • Rossi D, Modena V, Sciascia S, Roccatello D. Rheumatoid arthritis: biological therapy other than anti-TNF. Int Immunopharmacol. 2015;27:185–8.

    Article  CAS  PubMed  Google Scholar 

  • Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–26.

    Article  CAS  PubMed  Google Scholar 

  • Sciascia S, Talavera-Garcia E, Roccatelloa D, Baldovino S, Mengatti E, Cuadrado MJ. Upcoming biological therapies in systemic lupus erythematosus. Int Immunopharmacol. 2015;27:189–93.

    Article  CAS  PubMed  Google Scholar 

  • Souza FB, Porfírio GJ, Andriolo BN, Albuquerque JV, Trevisani VF. Rituximab effectiveness and safety for treating primary Sjögren’s syndrome (pSS): systematic review and meta-analysis. PLoS One. 2016;11:e0150749.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–7.

    Article  CAS  PubMed  Google Scholar 

  • Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185–96. https://doi.org/10.1002/mus.25597.

    Article  CAS  PubMed  Google Scholar 

  • Tendas A, Niscola P, Scaramucci L, Cupelli L, Perrotti AP, de Fabritiis P. Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. Blood Res. 2016;51:133–47.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Unit, Reference Center of Adults’ Autoimmune Cytopenia, CHU Henri Mondor, APHP, UPEC, 94010, Créteil, France

    Bertrand Godeau MD

Authors
  1. Bertrand Godeau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bertrand Godeau MD .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Medical Faculty of the University of Basel, Basel, Switzerland

    Paul Imbach

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Godeau, B. (2018). Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases. In: Imbach, P. (eds) Antibody Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-68038-5_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68038-5_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68037-8

  • Online ISBN: 978-3-319-68038-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation